A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Eligibility
Min Age: 50 YearsMax Age: 90 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying trontinemab — an antibody designed to clear amyloid plaques from the brain — in people with early symptomatic Alzheimer's disease. Amyloid plaques are protein deposits that accumulate in the brains of people with Alzheimer's and are thought to drive memory loss and thinking problems. The trial aims to determine whether trontinemab can slow the disease.
**You may be eligible if...**
- You have early Alzheimer's disease — either mild cognitive impairment (MCI) due to Alzheimer's or early-stage dementia
- Your amyloid plaques are confirmed by a PET brain scan or spinal fluid test
- Your memory and thinking score is 22 or above on the MMSE test, and your clinical dementia rating is 0.5 or 1.0
- You have a study partner who can assist with assessments and attend visits
- You have adequate vision and hearing to complete cognitive tests (aids are allowed)
**You may NOT be eligible if...**
- Your Alzheimer's is moderate or severe
- Amyloid has not been confirmed by scan or spinal fluid
- You have serious brain abnormalities on MRI
- You are on blood thinners or have other bleeding risks
- You are pregnant
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.